Compounds > sb 239063
Page last updated: 2024-08-16

sb 239063 and sb 203580

sb 239063 has been researched along with sb 203580 in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Chen, YD; Jiao, Y; Li, HF; Lu, T; Wang, X; Zhang, LY; Zhu, T1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Adams, JL; Badger, AM; Barone, FC; Erhardt, JA; Hunter, AJ; Irving, EA; Kassis, S; Kumar, S; Lee, JC; Legos, JJ; McVey, MJ; Nelson, AH; Ohlstein, EH; Parsons, AA; Ray, AM; Smith, BR; Ward, K; White, RF1
Cui, J; Feng, J; Li, Y; Shen, B; Wang, Q; Yu, M; Zhang, J; Zhu, N1
Gong, W; Holden, NS; King, EM; Newton, R; Rider, CF1

Other Studies

6 other study(ies) available for sb 239063 and sb 203580

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Pharmacophore identification of Raf-1 kinase inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Apr-01, Volume: 18, Issue:7

    Topics: Binding Sites; Biological Transport; Enzyme Inhibitors; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Models, Biological; Models, Chemical; Proto-Oncogene Proteins c-raf; Structure-Activity Relationship

2008
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 296, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Brain; Cerebrovascular Circulation; Enzyme Inhibitors; Hemodynamics; Hippocampus; Imidazoles; Inflammation; Ischemic Attack, Transient; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Organ Culture Techniques; p38 Mitogen-Activated Protein Kinases; Pyridines; Pyrimidines; Rats; Rats, Inbred Lew; Rats, Inbred SHR

2001
p38 MAPK contributes to CD54 expression and the enhancement of phagocytic activity during macrophage development.
    Cellular immunology, 2009, Volume: 256, Issue:1-2

    Topics: Animals; Antigens, Differentiation; CD11b Antigen; Cell Cycle; Cell Proliferation; Cell Survival; Enzyme Activation; Female; Imidazoles; In Vitro Techniques; Intercellular Adhesion Molecule-1; Lipopolysaccharide Receptors; Macrophage Activation; Macrophage Colony-Stimulating Factor; Macrophages; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 11; p38 Mitogen-Activated Protein Kinases; Phagocytosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines

2009
Inhibition of NF-kappaB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK.
    The Journal of biological chemistry, 2009, Sep-25, Volume: 284, Issue:39

    Topics: Blotting, Western; Cell Line; Cell Line, Tumor; Cycloheximide; Dactinomycin; Dexamethasone; Dose-Response Relationship, Drug; Dual Specificity Phosphatase 1; Enzyme Inhibitors; Gene Expression Regulation; Glucocorticoids; Humans; Imidazoles; Interleukin-8; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription, Genetic; Tumor Necrosis Factor-alpha

2009